Talazoparib

About

Therapy type: Targeted therapy

Therapy strategy: PARP inhibition

Mappings

NCI Thesaurus: Talazoparib (ncit:C95733)

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	RAD51B oncogenic variants	Prostate Adenocarcinoma	Talazoparib
Sensitivity (+)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (+)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	ATM pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	ATM oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	ATR oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	ATR pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	FANCA oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	FANCA pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	MLH1 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	MLH1 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	MRE11 oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	MRE11 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	NBN oncogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	NBN pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Enzalutamide, Talazoparib
Sensitivity (+)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (+)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib
Sensitivity (+)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Talazoparib